<DOC>
	<DOCNO>NCT02889666</DOCNO>
	<brief_summary>The purpose study determine commonly administer chemotherapeutic agent include cisplatin , carboplatin , oxaliplatin , docetaxel gemcitabine solid tumor clinical oncology , either single format give combination follow surgery effective treatment relapse refractory non-small cell lung cancer patient .</brief_summary>
	<brief_title>Cisplatin , Carboplatin , Oxaliplatin , Docetaxel Gemcitabine Plus Surgery Recurrent Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Lung carcinoma malignant disease characterize uncontrolled alveolar type II epithelial cell growth lung tissue . Worldwide 2012 , lung cancer occur 1.8 million people result 1.6 million death , make common cause cancer-related death men second common woman breast cancer . The common age diagnosis 70 year , less 20 % people diagnosed lung cancer survive five year post diagnosis . The two main type lung carcinomas small cell lung carcinoma ( SCLC ) non-small cell lung carcinoma ( NSCLC ) . NSCLC represent common type lung cancer , approximately 85 % lung cancer NSCLC . Squamous cell carcinoma , adenocarcinoma , large cell carcinoma subtypes NSCLC , latter associate high mortality overall cancer population limit treatment option . In study , investigator perform Phase I , open label , agent-combination exploration , multicenter clinical trial establish treatment efficacy several chemotherapeutic agent patient recurrent NSCLC undergone prior surgery primary disease . Up four cohort enrol determine effectiveness safety single combinational therapeutic strategy . Besides five-year disease-free survival , overall survival five-year metastasis-free survival post treatment , investigator also take account anticancer agent-induced tumor stroma damage extent , may provide evidence support treatment efficacy assess potential influence damage tumor microenvironment disease progression regression clinical setting .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Age ≤ 75 year histologically proven NSCLC No severe major organ dysfunction WHO performance status 0 1 No prior cancer chemotherapy A Clinical Stage ≥ IA ( T1a , N0 , M0 ) lung disease without diagnose distant metastasis ( accord 1997 revision International Union Against Cancer TNM stag system ) determine preoperative evaluation include pleural compute tomography ( CT ) scan . Age ≥ 76 Severe major organ dysfunction WHO performance status &gt; 1 Prior cancer chemotherapy Stage IV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>relapse</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>cisplatin</keyword>
	<keyword>carboplatin</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>docetaxel</keyword>
	<keyword>gemcitabine</keyword>
</DOC>